SPRY
ARS Pharmaceuticals, Inc.- Healthcare
- Biotechnology
- $401M market cap
Forecast run · Oct 29, 2026Upside rank 84 of 3,186
Model Signal
ForecastQ Daily Probabilities
64.8%
30.5%
48.5%
Analyst Consensus
Recommendation2.50/5 Buy
Last price$4.03
Price target$15.00
Implied move+272.2%
Analysts10
ForecastQ Portfolios
SPRY is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.